This new Whitepaper, sponsored by ThermoFisher Scientific, explores a scalable workflow for directly visualising LNPs in their near-native state and measuring critical quality attributes to support formulation optimisation, process development, and consistent therapeutic and vaccine delivery. Download now to: See beyond bulk measurements: Learn how cryo-TEM directly visualises individual LNPs in… Read More
Beam Therapeutics will present initial data from the ongoing Phase I/II clinical trial evaluating BEAM-301 for the treatment of glycogen storage disease type Ia (GSDIa) at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT). BEAM-301 is a liver-targeting lipid-nanoparticle (LNP) formulation… Read More
Memorial Sloan Kettering Cancer Center (MSK) and Quantoom Biosciences have executed a non-exclusive research license and supply agreement to support the development of personalised cancer therapies using Quantoom’s lipid nanoparticle (LNP) formulation technology, Ncapsulate QCX-002. Under the agreement, MSK will use Ncapsulate QCX-002, an LNP delivery chemistry… Read More
A new study has demonstrated the first stable, functional chimeric antigen receptor T-cells (CAR-T) cell generation in vivo using targeted lipid nanoparticles for DNA delivery. The research evaluated NanoCell Therapeutics’ targeted lipid nanoparticle delivery system, termed NCtx, which enables the… Read More
Researchers from the Peter Doherty Institute for Infection and Immunity in Melbourne have demonstrated a way to make HIV visible, paving the way to a complete cure. In a paper published in Nature Communications, the scientists have shown for the first time that… Read More
Scientists have developed a method for analysing the structure of lipid nanoparticles that could be used to improve vaccine and drug delivery. A team led by scientists at the University of Nottingham’s School of Pharmacy demonstrated a new cryogenic mass spectrometry approach for depth profiling frozen lipid… Read More
Vertex Pharmaceuticals and Orna Therapeutics have announced plans to partner on gene therapies for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The three-year strategic research collaboration will utilise Orna’s lipid nanoparticle (LNP) delivery solutions. In return Orna will receive upfront payments of $65 million, including an investment in… Read More
A new Guide is now available for free download from Cayman Chemical entitled ‘Lipid Nanoparticle Formulation: Basic Concepts & Preparation Procedures‘. Lipid nanoparticles (LNPs) have great potential to revolutionise the development of nucleic acid therapies. Download the Guide to learn more about: The basic concepts and components… Read More
Lipid nanoparticles (LNPs) have great potential to revolutionise the development of nucleic acid therapies. Download the Guide to learn more about: The basic concepts and components of lipid-based drug delivery systems Important considerations for LNP design, stability, and storage Techniques for LNP preparation, characterisation, and functional assessment… Read More
etherna has entered a research collaboration with Hasselt University (UHasselt) to develop an mRNA based treatment for autoimmune disorders. Funded by Flanders Innovation & Entrepreneurship (VLAIO), the project aims to combine etherna’s vast expertise in developing customised mRNA and lipid-based nanoparticle technologies for immuno-modulation with UHasselt’s research into autoimmune diseases… Read More
The strengths of etherna’s lipid based nanoparticle (LNP) platform have been showcased in a peer-reviewed paper in Advanced Functional Materials. etherna’s Vice President, Technology & Innovation, Stefaan De Koker described the paper as a “landmark” for the company and its technology. The RNA… Read More
